Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $30
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $20 to $30.
Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $20 to $30.